SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):275P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Price, E.
Right arrow Articles by Charron, M.
PubMed
Right arrow Articles by Price, E.
Right arrow Articles by Charron, M.

General Clinical Specialties: Pediatrics

Pediatrics Posters

18F-FDG PET/CT in pediatric oncology: Early experience at The Hospital for Sick Children

Elissa Price1, Ruth Lim2, Amer Shammas1 and Martin Charron1

1 Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; 2 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

1176

Objectives: To share early experience with 18F-FDG PET/CT in pediatric cancer patients from a tertiary care pediatric hospital. Techniques and impact on management are presented, in addition to selected interesting findings and pitfalls.

Methods: Retrospective review was performed of 18F-FDG PET/CT scans performed in the first 6 months (Feb-Jul 2007) of operation of our PET/CT scanner. Children with known or suspected tumors were imaged on a Philips Gemini GXL PET/CT scanner 1 hour after administration of 18F-FDG (0.14 mCi/kg). Feedback questionnaires were mailed to referring physicians.

Results: 54 PET/CT scans were performed in 44 children (M=25, F=19). Mean age was 11.9 yrs (range 3.2-17.9). Diagnoses were lymphoma (n=23), neuroblastoma (6), Ewing sarcoma (3), PTLD (3), and (n=1 each): osteosarcoma, GIST, adrenocortical carcinoma, thyroid carcinoma, AML, leiomyosarcoma, choroid plexus carcinoma, nerve sheath tumor and renal PNET. Feedback questionnaires were received for 32/54 scans (59% response). Indications were: staging 25% (8/32), response to therapy 18.8% (6/32), re-staging 15.6% (5/32), diagnosis 15.6% (5/32), post-treatment change vs. residual tumor 12.5% (4/32), suspected neoplasm 6.3% (2/32), monitor for recurrent tumor 3.1% (1/32), and unspecified 3.1% (1/32). In 46.7% (15/32), PET/CT resulted in change in management, although in no case was treatment goal changed from curative to palliative. In 40.6% (13/32), additional tests/procedures were avoided as a result of PET/CT.

Conclusions: 18F-FDG PET/CT contributes valuable information in the management of pediatric tumors, and in many cases can avoid the need for additional tests/procedures.

Research Support: Hospital for Sick Children, Department of Diagnostic Imaging





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Price, E.
Right arrow Articles by Charron, M.
PubMed
Right arrow Articles by Price, E.
Right arrow Articles by Charron, M.